NCT06348134

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 74 (estimated)
• Sponsor: University of Chicago · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Detailed description

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery. Participants with HER2-positive breast cancer will receive a combination of trastuzumab with pertuzumab (PHESGO) plus chemotherapy.

Conditions

• Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
• HER2-positive Breast Cancer
• Breast Cancer

Interventions

Type	Name	Description
DRUG	Trastuzumab emtansine	A chemotherapy drug.
DRUG	Pertuzumab Injection	A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
DRUG	Docetaxel	A chemotherapy drug.
DRUG	Tamoxifen	A medication used to treat breast cancer.
DRUG	Letrozole	A medication used to treat breast cancer.
DRUG	Goserelin	A hormone therapy drug.

Timeline

• Start date: 2025-03-18
• Primary completion: 2034-07-01
• Completion: 2036-07-01
• First posted: 2024-04-04
• Last updated: 2026-02-17

Locations

4 sites across 1 country: Nigeria